{"id":3371,"date":"2026-06-18T18:30:52","date_gmt":"2026-06-18T16:30:52","guid":{"rendered":"https:\/\/tetraneuron.com\/?p=3371"},"modified":"2026-06-18T18:30:52","modified_gmt":"2026-06-18T16:30:52","slug":"tetraneuron-receives-approval-to-initiate-first-in-human-clinical-testing-of-tet101-in-alzheimers-disease-patients-in-australia","status":"publish","type":"post","link":"https:\/\/tetraneuron.com\/en\/tetraneuron-receives-approval-to-initiate-first-in-human-clinical-testing-of-tet101-in-alzheimers-disease-patients-in-australia\/","title":{"rendered":"Tetraneuron receives approval to initiate first-in-human clinical testing of TET101 in Alzheimer\u2019s disease patients in Australia"},"content":{"rendered":"
Australia authorises the clinical evaluation of TET101, Tetraneuron\u2019s E2F4DN-based gene therapy programme with the potential to slow neurodegeneration and restore cognitive functions affected by Alzheimer\u2019s disease.<\/strong><\/h5>\n

Madrid, 17 June 2026 \u2014<\/strong>Tetraneuron, a Spanish biotechnology company focused on the development of gene therapies for neurodegenerative diseases, announces that it has received approval to proceed with first-in-human (FIH) clinical testing of TET101, its E2F4DN-based gene therapy programme for Alzheimer\u2019s disease, in Australia.<\/p>\n

The authorisation represents a transformative milestone for Tetraneuron, enabling TET101 to be evaluated for the first time in patients with Alzheimer\u2019s disease. The clinical trial will initially be conducted at St Vincent\u2019s Hospital Melbourne in Australia, an internationally recognised centre for clinical research, while the company continues to advance the regulatory procedures needed to extend the study to Europe. The programme will evaluate for the first time in humans the therapeutic potential of E2F4DN, an innovative gene therapy designed to act beyond traditional beta-amyloid and tau hypotheses, with the objective of slowing neurodegeneration, restoring neuronal function and supporting the recovery of cognitive capacities affected by the disease. <\/p>\n

Advancing towards clinical development in Alzheimer\u2019s disease<\/strong><\/h4>\n

Tetraneuron\u2019s TET101 programme is based on more than a decade of research into the role of E2F4 in neuronal function, cellular stress response, and neurodegenerative disease. The company\u2019s approach aims to go beyond symptomatic management by targeting biological pathways linked to neuronal survival, homeostasis, and brain function. <\/p>\n

The approval to proceed with human clinical testing in Australia represents an important step in translating this scientific work into clinical development. It also reinforces Tetraneuron\u2019s ambition to advance a potential disease-modifying therapeutic approach for Alzheimer\u2019s disease, an area of high unmet medical need worldwide. <\/p>\n

The potential of a platform for multiple neurodegenerative diseases<\/strong><\/h4>\n

Beyond Alzheimer\u2019s disease, Tetraneuron considers E2F4 to represent a new therapeutic platform for addressing multiple neurodegenerative diseases and processes associated with brain ageing. As a master regulator of neuronal homeostasis, E2F4 plays a key role in biological mechanisms shared by several neurodegenerative conditions. In addition to its clinical programme in Alzheimer\u2019s disease, the company has generated promising preclinical proof-of-concept data in Parkinson\u2019s disease, acquired hearing loss and cognitive decline associated with ageing. These results reinforce the potential of E2F4 as a therapeutic target capable of preserving and restoring neuronal function across a broad spectrum of diseases that currently lack curative treatments. <\/p>\n

About Tetraneuron<\/strong><\/h4>\n

Tetraneuron is a biotechnology company developing gene therapies for neurodegenerative diseases. Based in Madrid, Spain, the company’s proprietary platform targets E2F4, a master regulator of neuronal function, offering a multifactorial approach to treating and reverting Alzheimer’s disease at its source. For more information, visit www.tetraneuron.com<\/a> or contact info@tetraneuron.com.<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"

Australia authorises the clinical evaluation of TET101, Tetraneuron\u2019s E2F4DN-based gene therapy programme with the potential to slow neurodegeneration and restore cognitive functions affected by Alzheimer\u2019s disease. Madrid, 17 June 2026 \u2014Tetraneuron, a Spanish biotechnology company focused on the development of gene therapies for neurodegenerative diseases, announces that it has received approval to proceed with first-in-human … Read more<\/a><\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[13],"tags":[],"class_list":["post-3371","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"acf":[],"_links":{"self":[{"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/posts\/3371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/comments?post=3371"}],"version-history":[{"count":0,"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/posts\/3371\/revisions"}],"wp:attachment":[{"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/media?parent=3371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/categories?post=3371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/tags?post=3371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}